Seqirus | search
Click here to view Seqirus news from 60+ newspapers.
Bookmark or Share- For Seqirus, mRNA Offers The Next Big Breakthrough In Flu Vaccines - ForbesSeqirus was formed in 2015 when CSL purchased the Novartis influenza vaccines business, including a manufacturing site in Holly Springs, North Carolina. CSL employs around 27,000 people globally,...
- mRNA flu shots move into trials - NatureSeqirus stayed out of the COVID-19 vaccine race, despite having a self-amplifying mRNA platform that delivers both the antigen-coding sequence and the replication machinery needed for the...
- CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines ...CSL Seqirus is the only manufacturer to offer differentiated influenza vaccine options approved for use in individuals six months of age and older. This year's 2023/24 U.S. influenza season...
- Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of ...Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a...
- CSL Seqirus | A World Leader in Influenza VaccinesCSL Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the U.S., U.K. and Australia.
More
